At a glance
ClinicalIndex Comparison RecordPhase 2Active· 50 enrolled
Drug / intervention
TOOKAD Soluble 4 mg/kgdrug
Likely dose
TOOKAD Soluble 4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.
In Brief
A Phase 2 clinical trial evaluating TOOKAD Soluble 4 mg/kg for Localized Prostate Cancer. Active but no longer recruiting, targeting 50 participants across 1 site.
Detailed Summary
Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP in men with prostate cancer Gleason score 7(3+4).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocalized Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2ActiveOverdue
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedOct 2017
Primary CompletionNov 2020
Study CompletionFeb 2025
TodayJul 2026
First PostedOct 20, 2017
Enrollment StartOct 2, 2017
Primary CompletionNov 2, 2020
Study CompletionFeb 2, 2025
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 8.7 years ago
Interventions
TOOKAD Soluble 4 mg/kgdrug
Vascular targeted photodynamic therapy using TOOKAD Soluble